[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$frhdFLE_52W4aW-jaTPvOhL-7lm6Si9SwJZ6ViL0iGEw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":45,"rows":52},"University of Giessen",[4],95,false,21,8,115574,2,77,[14,17,19,22,25,27,30,32],{"name":15,"count":16},"Pulmonary Hypertension",11,{"name":18,"count":16},"Acute Kidney Injury",{"name":20,"count":21},"Heart Failure",5,{"name":23,"count":24},"Dysphagia",4,{"name":26,"count":24},"Stroke",{"name":28,"count":29},"Hypotension",3,{"name":31,"count":29},"Anesthesia",{"name":33,"count":29},"Type 2 Diabetes",[35,40],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT02131753","Therapy Optimisation for the Treatment of Hairy Cell Leukemia","2025-12","Cladribine s.c. injection, HCL treatment",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04444492","Combination of Ranibizumab and Targeted Laser Photocoagulation","2027-11-30","Ranibizumab",[46,47,48,49,50,51],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[53,78,100,128,146,164,201,229,247,274,292,321,339,364,393,420,438,465,483,510,536,554,580,610,628,646,664,691,709,727,745],{"intervention":39,"totalTrials":54,"cells":55},1,{"EARLY_PHASE1":56,"PHASE1":59,"PHASE2":61,"PHASE3":63,"PHASE4":74,"NA":76},{"trials":57,"activeCount":58},[],0,{"trials":60,"activeCount":58},[],{"trials":62,"activeCount":58},[],{"trials":64,"activeCount":54,"soonestReadout":38},[65],{"nctId":36,"briefTitle":37,"status":66,"phases":67,"primaryCompletion":38,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"RECRUITING",[48,49],"2027-12","2004-05",210,[72],"Hairy Cell Leukemia",[39],{"trials":75,"activeCount":58},[],{"trials":77,"activeCount":58},[],{"intervention":44,"totalTrials":54,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":96,"NA":98},{"trials":81,"activeCount":58},[],{"trials":83,"activeCount":58},[],{"trials":85,"activeCount":58},[],{"trials":87,"activeCount":54,"soonestReadout":43},[88],{"nctId":41,"briefTitle":42,"status":89,"phases":90,"primaryCompletion":43,"completion":43,"start":91,"enrollment":92,"conditions":93,"interventions":95},"ACTIVE_NOT_RECRUITING",[49],"2020-08-25",88,[94],"Central Retinal Vein Occlusion With Macular Edema",[44],{"trials":97,"activeCount":58},[],{"trials":99,"activeCount":58},[],{"intervention":101,"totalTrials":54,"cells":102},"Ciclosporin and Mycophenolate-mofetil",{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":126},{"trials":104,"activeCount":58},[],{"trials":106,"activeCount":58},[],{"trials":108,"activeCount":58},[],{"trials":110,"activeCount":58},[],{"trials":112,"activeCount":58},[113],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":123},"NCT00160966","Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy","COMPLETED",[50],"2010-03","2004-09",108,[122],"Polyomavirus Infections",[101,124,125],"Tacrolimus and Mycophenolate-mofetil","Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus",{"trials":127,"activeCount":58},[],{"intervention":124,"totalTrials":54,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":144},{"trials":131,"activeCount":58},[],{"trials":133,"activeCount":58},[],{"trials":135,"activeCount":58},[],{"trials":137,"activeCount":58},[],{"trials":139,"activeCount":58},[140],{"nctId":114,"briefTitle":115,"status":116,"phases":141,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":142,"interventions":143},[50],[122],[101,124,125],{"trials":145,"activeCount":58},[],{"intervention":125,"totalTrials":54,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":58},[],{"trials":151,"activeCount":58},[],{"trials":153,"activeCount":58},[],{"trials":155,"activeCount":58},[],{"trials":157,"activeCount":58},[158],{"nctId":114,"briefTitle":115,"status":116,"phases":159,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":160,"interventions":161},[50],[122],[101,124,125],{"trials":163,"activeCount":58},[],{"intervention":165,"totalTrials":11,"cells":166},"intravenous immunoglobulins",{"EARLY_PHASE1":167,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":197,"NA":199},{"trials":168,"activeCount":58},[169],{"nctId":170,"briefTitle":171,"status":116,"phases":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":179},"NCT00176059","Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients",[46],"2006-05","2001-10",50,[177,178],"Renal Failure, Chronic","Renal Transplantation",[165],{"trials":181,"activeCount":58},[],{"trials":183,"activeCount":58},[],{"trials":185,"activeCount":58},[186],{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":192,"start":193,"enrollment":58,"conditions":194,"interventions":196},"NCT00949065","Intravenous Immunoglobulins in Complex-regional Pain Syndrome","WITHDRAWN",[49],"2011-01","2011-02-15","2009-08",[195],"Complex Regional Pain Syndrome Type 1",[165],{"trials":198,"activeCount":58},[],{"trials":200,"activeCount":58},[],{"intervention":202,"totalTrials":54,"cells":203},"Bendamustine plus Rituximab",{"EARLY_PHASE1":204,"PHASE1":206,"PHASE2":208,"PHASE3":210,"PHASE4":225,"NA":227},{"trials":205,"activeCount":58},[],{"trials":207,"activeCount":58},[],{"trials":209,"activeCount":58},[],{"trials":211,"activeCount":58},[212],{"nctId":213,"briefTitle":214,"status":116,"phases":215,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":223},"NCT01456351","Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab",[49],"2010-08","2010-12","2003-09",230,[221,222],"Non-Hodgkin's Lymphoma","Mantle Cell Lymphoma",[202,224],"Fludarabine 25 mg\u002Fm² d 1-3 + Rituximab 375 mg\u002Fm² d 1 q4w",{"trials":226,"activeCount":58},[],{"trials":228,"activeCount":58},[],{"intervention":224,"totalTrials":54,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":243,"NA":245},{"trials":232,"activeCount":58},[],{"trials":234,"activeCount":58},[],{"trials":236,"activeCount":58},[],{"trials":238,"activeCount":58},[239],{"nctId":213,"briefTitle":214,"status":116,"phases":240,"primaryCompletion":216,"completion":217,"start":218,"enrollment":219,"conditions":241,"interventions":242},[49],[221,222],[202,224],{"trials":244,"activeCount":58},[],{"trials":246,"activeCount":58},[],{"intervention":248,"totalTrials":54,"cells":249},"cyclophosphamide, vincristine, prednisone, dacarbazine",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":270,"NA":272},{"trials":251,"activeCount":58},[],{"trials":253,"activeCount":58},[],{"trials":255,"activeCount":58},[],{"trials":257,"activeCount":58},[258],{"nctId":259,"briefTitle":260,"status":116,"phases":261,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT02684708","Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents",[49],"2024-10-31","2025-10-31","2015-10-01",2921,[267],"Classical Hodgkin Lymphoma",[248,269],"cyclo, vcr, pred, dacarb,etop and doxo",{"trials":271,"activeCount":58},[],{"trials":273,"activeCount":58},[],{"intervention":269,"totalTrials":54,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":288,"NA":290},{"trials":277,"activeCount":58},[],{"trials":279,"activeCount":58},[],{"trials":281,"activeCount":58},[],{"trials":283,"activeCount":58},[284],{"nctId":259,"briefTitle":260,"status":116,"phases":285,"primaryCompletion":262,"completion":263,"start":264,"enrollment":265,"conditions":286,"interventions":287},[49],[267],[248,269],{"trials":289,"activeCount":58},[],{"trials":291,"activeCount":58},[],{"intervention":293,"totalTrials":54,"cells":294},"Bendamustine",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":317,"NA":319},{"trials":296,"activeCount":58},[],{"trials":298,"activeCount":58},[],{"trials":300,"activeCount":58},[],{"trials":302,"activeCount":58},[303],{"nctId":304,"briefTitle":305,"status":116,"phases":306,"primaryCompletion":193,"completion":193,"start":307,"enrollment":308,"conditions":309,"interventions":315},"NCT00991211","Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",[49],"2004-01",549,[310,311,312,313,314],"Non-Hodgkin Lymphomas","Follicular Lymphomas","Immunocytomas","Lymphocytic Lymphomas","Marginal Zone Lymphomas",[293,316],"Standard chemotherapy CHOP + Ritiximab",{"trials":318,"activeCount":58},[],{"trials":320,"activeCount":58},[],{"intervention":316,"totalTrials":54,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":335,"NA":337},{"trials":324,"activeCount":58},[],{"trials":326,"activeCount":58},[],{"trials":328,"activeCount":58},[],{"trials":330,"activeCount":58},[331],{"nctId":304,"briefTitle":305,"status":116,"phases":332,"primaryCompletion":193,"completion":193,"start":307,"enrollment":308,"conditions":333,"interventions":334},[49],[310,311,312,313,314],[293,316],{"trials":336,"activeCount":58},[],{"trials":338,"activeCount":58},[],{"intervention":340,"totalTrials":54,"cells":341},"Cernilton",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":360,"NA":362},{"trials":343,"activeCount":58},[],{"trials":345,"activeCount":58},[],{"trials":347,"activeCount":58},[],{"trials":349,"activeCount":58},[350],{"nctId":351,"briefTitle":352,"status":116,"phases":353,"primaryCompletion":307,"completion":307,"start":354,"enrollment":355,"conditions":356,"interventions":359},"NCT00919893","Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)",[49],"1999-12",139,[357,358],"Chronic Prostatitis","Chronic Pelvic Pain Syndrome",[340],{"trials":361,"activeCount":58},[],{"trials":363,"activeCount":58},[],{"intervention":365,"totalTrials":54,"cells":366},"Rituximab",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":368,"activeCount":58},[],{"trials":370,"activeCount":58},[],{"trials":372,"activeCount":58},[373],{"nctId":374,"briefTitle":375,"status":116,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":386},"NCT01136395","Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation",[48],"2019-06-18","2010-01",85,[381,382,383,384,385],"Kidney Transplantation","Rituximab (RTx)","Living Donors","Immunology","Virus",[365],{"trials":388,"activeCount":58},[],{"trials":390,"activeCount":58},[],{"trials":392,"activeCount":58},[],{"intervention":394,"totalTrials":54,"cells":395},"inhaled molgramostim",{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":397,"activeCount":58},[],{"trials":399,"activeCount":58},[],{"trials":401,"activeCount":58},[402],{"nctId":403,"briefTitle":404,"status":116,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":412},"NCT02595060","Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration",[48],"2021-09-22","2022-07-31","2016-06-01",45,[411],"ARDS",[394,413],"inhaled placebo",{"trials":415,"activeCount":58},[],{"trials":417,"activeCount":58},[],{"trials":419,"activeCount":58},[],{"intervention":413,"totalTrials":54,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":423,"activeCount":58},[],{"trials":425,"activeCount":58},[],{"trials":427,"activeCount":58},[428],{"nctId":403,"briefTitle":404,"status":116,"phases":429,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":430,"interventions":431},[48],[411],[394,413],{"trials":433,"activeCount":58},[],{"trials":435,"activeCount":58},[],{"trials":437,"activeCount":58},[],{"intervention":439,"totalTrials":54,"cells":440},"Riciguat Group",{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":442,"activeCount":58},[],{"trials":444,"activeCount":58},[],{"trials":446,"activeCount":58},[447],{"nctId":448,"briefTitle":449,"status":116,"phases":450,"primaryCompletion":451,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":457},"NCT03362047","(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)",[48],"2024-07-03","2024-08-14","2018-03-01",7,[456],"Pulmonary Arterial Hypertension (PAH)",[439,458],"Macitentan Group",{"trials":460,"activeCount":58},[],{"trials":462,"activeCount":58},[],{"trials":464,"activeCount":58},[],{"intervention":458,"totalTrials":54,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":468,"activeCount":58},[],{"trials":470,"activeCount":58},[],{"trials":472,"activeCount":58},[473],{"nctId":448,"briefTitle":449,"status":116,"phases":474,"primaryCompletion":451,"completion":452,"start":453,"enrollment":454,"conditions":475,"interventions":476},[48],[456],[439,458],{"trials":478,"activeCount":58},[],{"trials":480,"activeCount":58},[],{"trials":482,"activeCount":58},[],{"intervention":484,"totalTrials":54,"cells":485},"Molgramostim nebuliser solution",{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":504,"PHASE4":506,"NA":508},{"trials":487,"activeCount":58},[],{"trials":489,"activeCount":58},[],{"trials":491,"activeCount":58},[492],{"nctId":493,"briefTitle":494,"status":116,"phases":495,"primaryCompletion":496,"completion":497,"start":498,"enrollment":499,"conditions":500,"interventions":503},"NCT04569877","GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia",[48],"2022-06-21","2022-09-20","2020-09-24",63,[501,502],"Severe Acute Respiratory Syndrome (SARS) Pneumonia","COVID-19 Pneumonia",[484],{"trials":505,"activeCount":58},[],{"trials":507,"activeCount":58},[],{"trials":509,"activeCount":58},[],{"intervention":511,"totalTrials":54,"cells":512},"insulin glargine",{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":523},{"trials":514,"activeCount":58},[],{"trials":516,"activeCount":58},[],{"trials":518,"activeCount":58},[],{"trials":520,"activeCount":58},[],{"trials":522,"activeCount":58},[],{"trials":524,"activeCount":58},[525],{"nctId":526,"briefTitle":527,"status":116,"phases":528,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT00468364","Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes",[],"2006-03","2003-07",12,[533],"Diabetes",[511,535],"NPH insulin",{"intervention":535,"totalTrials":54,"cells":537},{"EARLY_PHASE1":538,"PHASE1":540,"PHASE2":542,"PHASE3":544,"PHASE4":546,"NA":548},{"trials":539,"activeCount":58},[],{"trials":541,"activeCount":58},[],{"trials":543,"activeCount":58},[],{"trials":545,"activeCount":58},[],{"trials":547,"activeCount":58},[],{"trials":549,"activeCount":58},[550],{"nctId":526,"briefTitle":527,"status":116,"phases":551,"completion":529,"start":530,"enrollment":531,"conditions":552,"interventions":553},[],[533],[511,535],{"intervention":555,"totalTrials":54,"cells":556},"Iloprost",{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":561,"PHASE3":563,"PHASE4":565,"NA":567},{"trials":558,"activeCount":58},[],{"trials":560,"activeCount":58},[],{"trials":562,"activeCount":58},[],{"trials":564,"activeCount":58},[],{"trials":566,"activeCount":58},[],{"trials":568,"activeCount":58},[569],{"nctId":570,"briefTitle":571,"status":116,"phases":572,"primaryCompletion":573,"completion":574,"start":575,"enrollment":576,"conditions":577,"interventions":579},"NCT03365479","Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension",[51],"2018-08-01","2018-10-24","2017-05-01",30,[15,578],"Pulmonary Arterial Hypertension",[555],{"intervention":581,"totalTrials":54,"cells":582},"Rifampicin",{"EARLY_PHASE1":583,"PHASE1":585,"PHASE2":587,"PHASE3":589,"PHASE4":591,"NA":593},{"trials":584,"activeCount":58},[],{"trials":586,"activeCount":58},[],{"trials":588,"activeCount":58},[],{"trials":590,"activeCount":58},[],{"trials":592,"activeCount":58},[],{"trials":594,"activeCount":58},[595],{"nctId":596,"briefTitle":597,"status":116,"phases":598,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":606},"NCT02554318","Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia",[51],"2015-02","2013-11",147,[603,604,605],"Pulmonary Tuberculosis","Body Weight Changes","Motor Activity",[581,607,608,609],"Isoniazid","Pyrazinamide","Ethambutol",{"intervention":607,"totalTrials":54,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":613,"activeCount":58},[],{"trials":615,"activeCount":58},[],{"trials":617,"activeCount":58},[],{"trials":619,"activeCount":58},[],{"trials":621,"activeCount":58},[],{"trials":623,"activeCount":58},[624],{"nctId":596,"briefTitle":597,"status":116,"phases":625,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":626,"interventions":627},[51],[603,604,605],[581,607,608,609],{"intervention":608,"totalTrials":54,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":58},[],{"trials":633,"activeCount":58},[],{"trials":635,"activeCount":58},[],{"trials":637,"activeCount":58},[],{"trials":639,"activeCount":58},[],{"trials":641,"activeCount":58},[642],{"nctId":596,"briefTitle":597,"status":116,"phases":643,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":644,"interventions":645},[51],[603,604,605],[581,607,608,609],{"intervention":609,"totalTrials":54,"cells":647},{"EARLY_PHASE1":648,"PHASE1":650,"PHASE2":652,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":649,"activeCount":58},[],{"trials":651,"activeCount":58},[],{"trials":653,"activeCount":58},[],{"trials":655,"activeCount":58},[],{"trials":657,"activeCount":58},[],{"trials":659,"activeCount":58},[660],{"nctId":596,"briefTitle":597,"status":116,"phases":661,"primaryCompletion":599,"completion":599,"start":600,"enrollment":601,"conditions":662,"interventions":663},[51],[603,604,605],[581,607,608,609],{"intervention":665,"totalTrials":54,"cells":666},"cyclosporine A",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":673,"PHASE4":675,"NA":677},{"trials":668,"activeCount":58},[],{"trials":670,"activeCount":58},[],{"trials":672,"activeCount":58},[],{"trials":674,"activeCount":58},[],{"trials":676,"activeCount":58},[],{"trials":678,"activeCount":58},[679],{"nctId":680,"briefTitle":681,"status":116,"phases":682,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":687},"NCT00150891","Th1, Th2 and Monokine Responses as Risk Factors of Renal Transplant Rejection",[],"2006-01","1998-01",84,[177],[665,688,689,690],"tacrolimus","azathioprine","mycophenolate mofetil",{"intervention":688,"totalTrials":54,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":703},{"trials":694,"activeCount":58},[],{"trials":696,"activeCount":58},[],{"trials":698,"activeCount":58},[],{"trials":700,"activeCount":58},[],{"trials":702,"activeCount":58},[],{"trials":704,"activeCount":58},[705],{"nctId":680,"briefTitle":681,"status":116,"phases":706,"completion":683,"start":684,"enrollment":685,"conditions":707,"interventions":708},[],[177],[665,688,689,690],{"intervention":689,"totalTrials":54,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":721},{"trials":712,"activeCount":58},[],{"trials":714,"activeCount":58},[],{"trials":716,"activeCount":58},[],{"trials":718,"activeCount":58},[],{"trials":720,"activeCount":58},[],{"trials":722,"activeCount":58},[723],{"nctId":680,"briefTitle":681,"status":116,"phases":724,"completion":683,"start":684,"enrollment":685,"conditions":725,"interventions":726},[],[177],[665,688,689,690],{"intervention":690,"totalTrials":54,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":733,"PHASE3":735,"PHASE4":737,"NA":739},{"trials":730,"activeCount":58},[],{"trials":732,"activeCount":58},[],{"trials":734,"activeCount":58},[],{"trials":736,"activeCount":58},[],{"trials":738,"activeCount":58},[],{"trials":740,"activeCount":58},[741],{"nctId":680,"briefTitle":681,"status":116,"phases":742,"completion":683,"start":684,"enrollment":685,"conditions":743,"interventions":744},[],[177],[665,688,689,690],{"intervention":746,"totalTrials":54,"cells":747},"Glibenclamide",{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":749,"activeCount":58},[],{"trials":751,"activeCount":58},[],{"trials":753,"activeCount":58},[],{"trials":755,"activeCount":58},[],{"trials":757,"activeCount":58},[],{"trials":759,"activeCount":58},[760],{"nctId":761,"briefTitle":762,"status":116,"phases":763,"primaryCompletion":764,"completion":765,"start":766,"enrollment":531,"conditions":767,"interventions":768},"NCT00734669","Risk of Hypoglycemia in Type 2 Diabetes",[],"2016-01","2016-10","2008-07",[33],[746]]